The information printed herein is derived from our own laboratories and other sources, and is believed to be accurate. However, it may be modified by later findings and should be used with this understanding. Nothing herein shall be construed as a recommendation to use any product in violation of any patent rights. The user shall have sole responsibility for determination of whether this product is suitable for any particular purpose. Prior to use, refer to the Material Safety Data Sheet for assistance in determining safe handling, storage, and use procedures.

**PRODUCT SPECIFICATIONS**

**FORMULA**
C₉H₁₁N·C₂H₇NO₄·H₂O

**MOLECULAR WEIGHT**
286.31

**APPEARANCE**
White to off-white solid

**IDENTIFICATION**
IR: Matches standard

**SPECIFIC ROTATION**
Optically inactive

**LOSS ON DRYING**
5.3 – 7.3% w/w

**RESIDUE ON IGNITION**
0.2% Max

**pH**
6.0 – 7.0

**ASSAY (HPLC) (DRIED BASIS)**
98.0 – 102.0% w/w

**RELATED SUBSTANCES**
- Cathinone Aspartate: 0.15% w/w Max
- Benzaldehyde: 0.15% w/w Max
- 1-Phenyl-2-Propanol: 0.15% w/w Max
- Phenylacetone: 0.15% w/w Max
- Unknown rel. subs. (each): 0.10% w/w Max
- Total rel. subs.: 0.50% w/w Max

**NICKEL (as Ni)(ICP)**
50 ppm Max

**RESIDUAL SOLVENTS (GC)**
- Methanol: 3000 ppm Max
- Ethanol: 5000 ppm Max

---

**Amphetamine Aspartate**

**ITEM CODE** 3993

![Amphetamine Aspartate Chemical Structure]

**AMPHETAMINE ASPARTATE**, Dextroamphetamine Saccharate, Dextroamphetamine Sulfate and Amphetamine Sulfate, in fixed combination, are indicated for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), most commonly diagnosed as a childhood disorder. This combination product is an integral part of a total treatment program, which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by moderate to severe distractibility, short attention span, hyperactivity, emotional liability and impulsivity.

Common Trade Name:  Adderall®

*Effective 3/2014*